Posology : מינונים

4.2 Posology and method of administration
Posology

Table 1. Adults and children ≥ 40 kg
Indication                                             Dosage
Community acquired pneumonia and acute                 750 mg every 8 hours exacerbations of chronic bronchitis                    (intravenously or intramuscularly) Soft-tissue infections: cellulitis, erysipelas and wound infections.
Intra-abdominal infections
Sinusitis, septic arthritis                            750 mg every 8 hours (intravenously or intramuscularly). For more severe infections, this dose should be increased to 1.5g every 8 hours i.v. The frequency of i.m. or i.v. injections can be increased to six-hourly if necessary, giving total doses of 3g to 6g daily. Where clinically indicated, some infections respond to 750 mg or 1.5 g twice daily (i.v. or i.m.)
Complicated urinary tract infections, including        1.5 g every 8 hours (intravenously pyelonephritis                                         or intramuscularly) Severe infections                                      750 mg every 6 hours (intravenously) 1.5 g every 8 hours (intravenously)

Surgical prophylaxis for gastrointestinal,             1.5 g with the induction of anaesthesia. This gynaecological surgery (including caesarean            may be supplemented with two 750 mg section) and orthopaedic operations                    doses (intramuscularly) after 8 hours and 16 hours
Surgical prophylaxis for cardiovascular and            1.5 g with induction of anaesthesia followed oesophageal operations                                 by 750 mg (intramuscularly) every 8 hours for a further 24 hours


Table 2. Children < 40 kg
Infants and toddlers > 3 weeks        Infants (birth to 3 weeks) and children < 40 kg
Community acquired pneumonia 30 to 100 mg/kg/day                           30 to 100 mg/kg/day Complicated urinary tract            (intravenously) given as 3 infections, including pyelonephritis or 4 divided doses; a dose            (intravenously) given as Soft-tissue infections: cellulitis,  of 60 mg/kg/day is                    2 or 3 divided doses (see erysipelas and wound infections      appropriate for most                  section 5.2) Intra-abdominal infections           infections
Sinusitis, septic arthritis          Doses of 30 to 100 mg/kg/day          Doses of 30 to 100 given as three or four divided        mg/kg/day given as two doses. A dose of 60mg/kg/day is       or three divided doses.
appropriate for most infections.



Renal impairment

Cefuroxime is primarily excreted by the kidneys. Therefore, as with all such antibiotics, in patients with markedly impaired renal function it is recommended that the dosage of CEFUROXIME BE PHARMA 750 MG should be reduced to compensate for its slower excretion.

Table 3. Recommended doses for CEFUROXIME BE PHARMA 750 MG in renal impairment Creatinine clearance       T1/2 (hrs)              Dose (mg)
> 20 mL/min/1.73 m2              1.7–2.6         It is not necessary to reduce the standard dose (750 mg to 1.5 g three times daily).


10-20 mL/min/1.73 m2             4.3–6.5         750 mg twice daily 
< 10 mL/min/1.73 m2              14.8–22.3       750 mg once daily

Patients on haemodialysis        3.75            A further 750 mg dose should be given intravenously or intramuscularly at the end of each dialysis; in addition to parenteral use, cefuroxime sodium can be incorporated into the peritoneal dialysis fluid (usually 250 mg for every 2 litres of dialysis fluid).


Patients in renal failure on 7.9–12.6            750 mg twice daily; for low-flux haemofiltration continuous        arteriovenous (CAVH)           follow the dosage recommended under impaired haemodialysis (CAVH) or 1.6 (HF)                 renal function.
high- flux haemofiltration (HF) in intensive therapy units


Hepatic impairment

Cefuroxime is primarily eliminated by the kidney. In patients with hepatic dysfunction this is not expected to affect the pharmacokinetics of cefuroxime.

Method of administration

CEFUROXIME BE PHARMA 750 MG should be administered by intravenous injection over a period of 3 to 5 minutes directly into a vein or via a drip tube or infusion over 30 to 60 minutes, or by deep intramuscular injection.

Intramuscular injections should be injected well within the bulk of a relatively large muscle and not more than 750 mg should be injected at one site. For doses greater than 1.5 g intravenous administration should be used. For instructions on reconstitution of the medicinal product before administration, see section 6.6.